Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 3/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | THPO | P40225 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N6-Cyclopentyladenosine SCHEMBL12226873 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL7202975 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL8271466 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL472508 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL472621 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL12200134 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL20226050 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL120481 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| N6-Cyclopentyladenosine SCHEMBL18908968 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 | |
| SCHEMBL12119008 | 0.99 | TSHR (1.00) | ADORA3ADORA2ATSHRADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118845814-A | Application of N6-cyclopentyl adenosine, derivatives and salts thereof in treating liver diseases | 上海中医药大学 | 2024-10-29 | — | — | CN | claimed |
| EP-2704793-B1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV RAMOT (IL) | 2019-07-17 | — | — | EP | claimed |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2018-12-06 | — | — | US | claimed |
| WO-2016183217-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY (US) | 2016-11-17 | — | — | WO | claimed |
| EP-2204154-B1 | Association of monosaccharides and adenosine and its cosmetic use | ORÉAL L (FR) | 2016-10-12 | — | — | EP | claimed |
| US-9192670-B2 | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-11-24 | — | — | US | claimed |
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED | 2011-08-25 | — | — | US | claimed |
| EP-2328577-A1 | THE TREATMENT OF HEARING LOSS | Auckland UniServices Limited (NZ) | 2011-06-08 | — | — | EP | claimed |
| WO-2010019057-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-02-18 | — | — | WO | claimed |
| JP-2004520404-A | — | — | 2004-07-08 | — | — | JP | claimed |
| EP-0996453-B1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | MOHLER HANNS (CH) | 2004-04-28 | — | — | EP | claimed |
| EP-1363644-A2 | MODULATION OF GSK-3BETA ACTIVITY AND ITS DIFFERENT USES | Can-Fite Biopharma Ltd. (IL) | 2003-11-26 | — | — | EP | claimed |
| US-6638914-B1 | Use in inducing proliferation of the hematopoietic system, in particular, of bone marrow cells, comprising a pharmaceutically acceptable carrier, excipient or diluent and, as an active ingredient, an effective amount of an | CAN-FITE BIOPHARMA LTD. (IL) | 2003-10-28 | — | — | US | claimed |
| WO-2002066020-A2 | MODULATION OF GSK-3BETA ACTIVITY AND ITS DIFFERENT USES | CAN-FITE BIOPHARMA LTD. (IL) | 2002-08-29 | — | — | WO | claimed |
| US-20260008805-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250295604-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2025-09-25 | — | — | US | disclosed |
| EP-4590677-A2 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | Biointervene, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-1993008206-A1 | NOVEL 2,6-DISUBSTITUTED PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-04-29 | — | — | WO | disclosed |
| WO-1988000192-A1 | 5-SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY (US) | 1988-01-14 | — | — | WO | disclosed |
| EP-0232813-A2 | N6-substituted Adenosines | WARNER-LAMBERT COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA2A 2/4885TSHR 561/4885 |
| US-20260008805-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | ADORA2B, ADORA2A, ADORA1 | ADORA3 4/4885ADORA2A 2/4885TSHR 561/4885 |
| US-20250295604-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA3 32/4885ADORA2A 10/4885TSHR 3522/4885 |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA3 32/4885ADORA2A 10/4885TSHR 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.